Biomarkers of Systemic Inflammation and Risk of Incident, Symptomatic Benign Prostatic Hyperplasia: Results From the Prostate Cancer Prevention Trial

The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993–2003). Incident BPH (n = 676) was defined as treatment, report of 2 International...

Full description

Saved in:
Bibliographic Details
Published in:American journal of epidemiology 2010-03, Vol.171 (5), p.571-582
Main Authors: Schenk, Jeannette M., Kristal, Alan R., Neuhouser, Marian L., Tangen, Catherine M., White, Emily, Lin, Daniel W., Kratz, Mario, Thompson, Ian M.
Format: Article
Language:English
Subjects:
Aged
Biological and medical sciences
Biomarkers
Biomarkers - blood
C-Reactive Protein - metabolism
Gynecology. Andrology. Obstetrics
Humans
inflammation
Inflammation - complications
Inflammation - immunology
Inflammatory diseases
Interferon-gamma - blood
Interleukin-6 - blood
Male
Male genital diseases
Medical sciences
Mens health
Metabolic diseases
Middle Aged
Nephrology. Urinary tract diseases
Obesity
Original Contributions
Prostate
prostatic hyperplasia
Prostatic Hyperplasia - epidemiology
Prostatic Hyperplasia - immunology
Prostatic Neoplasms - prevention & control
Receptors, Tumor Necrosis Factor - blood
Risk Assessment
Risk Factors
Tumor Necrosis Factor-alpha - blood
Tumors
Tumors of the urinary system
Urinary tract. Prostate gland
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The authors conducted a nested case-control study of serum inflammatory markers and risk of symptomatic benign prostatic hyperplasia (BPH), using data from the placebo arm of the Prostate Cancer Prevention Trial (1993–2003). Incident BPH (n = 676) was defined as treatment, report of 2 International Prostate Symptom Score (IPSS) values >14, or 2 increases of ≥5 from baseline values with at least one value ≥12. Controls (n = 683) were men who reported no BPH treatment or IPSS values >7 over the 7-year trial. Baseline serum was analyzed for C-reactive protein, tumor necrosis factor α (monomer), soluble tumor necrosis factor receptors I and II (sTNF-RI and sTNF-RII), interleukin 6, and interferon γ. Controlled for age and race, a high C-reactive protein concentration was associated with increased BPH risk (for quartile 4 vs. quartile 1, odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.04, 1.88); this was attenuated after control for body mass index (OR = 1.30, 95% CI: 0.95, 1.75). Low sTNF-RII and high interleukin 6 concentrations were associated with increased BPH risk (for quartile 4 vs. quartile 1, sTNF-RII: OR = 0.61, 95% CI: 0.46, 0.82; interleukin 6: OR = 1.79, 95% CI: 1.32, 2.42); these associations were only in men aged
ISSN:0002-9262
1476-6256
DOI:10.1093/aje/kwp406